Role of Optimal Medication Given to Patients with Hypertension and Ischemic Heart Disease Prior to an Acute Coronary Syndrome.

IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Heart International Pub Date : 2017-10-14 eCollection Date: 2017-01-01 DOI:10.5301/heartint.5000237
Călin Pop, Roberta Florescu, Claudia Matei, Lavinia Pop, Viorel Manea, Coralia Cotoraci, Liana Mos, Antoniu Petris
{"title":"Role of Optimal Medication Given to Patients with Hypertension and Ischemic Heart Disease Prior to an Acute Coronary Syndrome.","authors":"Călin Pop,&nbsp;Roberta Florescu,&nbsp;Claudia Matei,&nbsp;Lavinia Pop,&nbsp;Viorel Manea,&nbsp;Coralia Cotoraci,&nbsp;Liana Mos,&nbsp;Antoniu Petris","doi":"10.5301/heartint.5000237","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Administering optimal cardiovascular medication (OCM) to patients with hypertension (HBP) and ischemic heart disease (IHD) lowers cardiovascular morbidity and mortality.The main objective of this study was to compare in-hospital cardiac mortality among patients with HBP and/or IHD, treated or untreated with OCM, who developed a first episode of acute coronary syndrome (ACS).</p><p><strong>Methods: </strong>The study was carried out retrospectively and included patients admitted with a first episode of ACS between 2013 and 2016. The patients were divided into three groups: those with HBP, IHD, and a history of HBP + IHD. Patients were then divided into two subgroups: subgroup A consisted of patients undergoing optimal anti-ischemic and/or antihypertensive therapy, while subgroup B consisted of patients without OCM.</p><p><strong>Results: </strong>This analysis comprised 1096 patients. Mean age was 64.3 ± 18 years. There were 581 patients in subgroup A - 53%, and 515 patients in subgroup B - 47%. Total cardiac mortality was 9.98%, different depending on the groups and subgroups studied: HBP group total - 7%, subgroup A - 5.1%, significantly lower compared to subgroup B - 9.4% (p = 0.05); IHD group total - 12.2%, subgroup A - 9.07%, significantly lower compared to subgroup B - 15.8% (p = 0.05); HBP + IHD group total - 14.35%, subgroup A - 9.9%, significantly lower compared to subgroup B - 18.8% (p = 0.05).</p><p><strong>Conclusions: </strong>The lack of OCM in patients with HBP and/or IHD is correlated to a significant increase in in-hospital cardiac mortality among patients who develop a first-episode ACS.</p>","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"12 1","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2017-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5301/heartint.5000237","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5301/heartint.5000237","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 1

Abstract

Introduction: Administering optimal cardiovascular medication (OCM) to patients with hypertension (HBP) and ischemic heart disease (IHD) lowers cardiovascular morbidity and mortality.The main objective of this study was to compare in-hospital cardiac mortality among patients with HBP and/or IHD, treated or untreated with OCM, who developed a first episode of acute coronary syndrome (ACS).

Methods: The study was carried out retrospectively and included patients admitted with a first episode of ACS between 2013 and 2016. The patients were divided into three groups: those with HBP, IHD, and a history of HBP + IHD. Patients were then divided into two subgroups: subgroup A consisted of patients undergoing optimal anti-ischemic and/or antihypertensive therapy, while subgroup B consisted of patients without OCM.

Results: This analysis comprised 1096 patients. Mean age was 64.3 ± 18 years. There were 581 patients in subgroup A - 53%, and 515 patients in subgroup B - 47%. Total cardiac mortality was 9.98%, different depending on the groups and subgroups studied: HBP group total - 7%, subgroup A - 5.1%, significantly lower compared to subgroup B - 9.4% (p = 0.05); IHD group total - 12.2%, subgroup A - 9.07%, significantly lower compared to subgroup B - 15.8% (p = 0.05); HBP + IHD group total - 14.35%, subgroup A - 9.9%, significantly lower compared to subgroup B - 18.8% (p = 0.05).

Conclusions: The lack of OCM in patients with HBP and/or IHD is correlated to a significant increase in in-hospital cardiac mortality among patients who develop a first-episode ACS.

Abstract Image

Abstract Image

Abstract Image

急性冠脉综合征前高血压和缺血性心脏病患者最佳用药的作用
对高血压(HBP)和缺血性心脏病(IHD)患者给予最佳心血管药物(OCM)可降低心血管发病率和死亡率。本研究的主要目的是比较首次发生急性冠状动脉综合征(ACS)的HBP和/或IHD患者(接受或未接受OCM治疗)的住院心脏死亡率。方法:回顾性研究纳入2013年至2016年间首次发作ACS的患者。患者被分为三组:有HBP、IHD和有HBP + IHD病史的患者。然后将患者分为两个亚组:亚组由接受最佳抗缺血和/或抗高血压治疗的患者组成,而亚组由未接受OCM治疗的患者组成。结果:本分析共纳入1096例患者。平均年龄64.3±18岁。A亚组581例,占53%;B亚组515例,占47%。心脏总死亡率为9.98%,因组和亚组而异:HBP组总死亡率为7%,A亚组为5.1%,显著低于B亚组9.4% (p = 0.05);IHD组总- 12.2%,A亚组- 9.07%,显著低于B亚组- 15.8% (p = 0.05);HBP + IHD组总- 14.35%,A亚组- 9.9%,显著低于B亚组- 18.8% (p = 0.05)。结论:HBP和/或IHD患者缺乏OCM与首发ACS患者院内心脏死亡率显著增加相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Heart International
Heart International Medicine-Cardiology and Cardiovascular Medicine
CiteScore
0.90
自引率
0.00%
发文量
9
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信